# Reversibility of cerebrovascular endothelial dysfunction in patients with diabetes

Submission date	Recruitment status  No longer recruiting	<ul><li>Prospectively registered</li></ul>		
08/09/2005		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
27/10/2005	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
23/08/2013	Nutritional, Metabolic, Endocrine			

## Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Matthew Walters

#### Contact details

Department of Medicine & Therapeutics Western Infirmary 44 Church Street Glasgow United Kingdom G11 6NT +44 (0)141 211 2821 gcl203@clinmed.gla.ac.uk

# Additional identifiers

# EudraCT/CTIS number

2005-001670-27

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

# Study information

#### Scientific Title

#### Study objectives

The purpose of the study is to investigate the effect of both losartan and atenolol upon impaired cerebrovascular reactivity in diabetic patients.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

## Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

# Study type(s)

Treatment

#### Participant information sheet

#### Health condition(s) or problem(s) studied

Diabetes

#### **Interventions**

Patients will undergo baseline assessment of cerebrovascular reactivity, mean flow velocity (MFV) in the middle cerebral artery (MCA) will be measured using transcranial Doppler. Each subject will then receive an intravenous infusion of L-NMMA after which MFV will be measured as before. Mean flow velocity in the internal carotid artery and peripheral arterial stiffness using Sphygmocor will also be assessed pre- and post-infusion for comparison. Patients then receive a supply of either losartan or atenolol tablets for 2 weeks after which they will undergo the same protocol as before. A 2-week washout period of no medication will follow, then the protocol repeated with the alternate tablet.

#### Intervention Type

Drug

#### **Phase**

#### Drug/device/biological/vaccine name(s)

Losartan and atenolol

#### Primary outcome measure

The aim of the study is to investigate the potential reversibility of the observed impairment of endothelial function.

#### Secondary outcome measures

Not provided at time of registration

#### Overall study start date

01/07/2005

#### Completion date

01/07/2006

# **Eligibility**

#### Key inclusion criteria

- 1. Type II diabetes <5 years duration
- 2. Age >40 years
- 3. Normal full Bruce protocol exercise tolerance test

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Sex

Both

#### Target number of participants

18

#### Key exclusion criteria

- 1. >70% internal carotid artery (ICA) stenosis
- 2. Significant comorbidity
- 3. Contra-indication to administration of angiotensin II receptor blocker (ARB)/angiotensin converting enzyme (ACE)-1/beta-blocker
- 4. Ongoing treatment with ARB/ACE1/beta-blocker unless can be withdrawn 4 weeks prior to randomisation

#### Date of first enrolment

01/07/2005

#### Date of final enrolment

01/07/2006

# Locations

#### Countries of recruitment

Scotland

**United Kingdom** 

Study participating centre

Department of Medicine & Therapeutics

Glasgow

United Kingdom

G11 6NT

# Sponsor information

# Organisation

University of Glasgow (UK)

# Sponsor details

University Avenue Glasgow Scotland United Kingdom G11 6NT +44 (0)141 339 8855 pcn1w@clinmed.gla.ac.uk

# Sponsor type

University/education

#### **ROR**

https://ror.org/00vtgdb53

# Funder(s)

#### Funder type

University/education

#### **Funder Name**

University of Glasgow (UK)

## Alternative Name(s)

# **Funding Body Type**

Private sector organisation

# Funding Body Subtype

Universities (academic only)

#### Location

**United Kingdom** 

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2009		Yes	No